drugset
drugset / Trial / NCT03609398

Phase 2 Safety and Immunogenicity Study of Rift Valley Fever Vaccine

NCT03609398 ↗

Phase 2 Recruiting 500 enrolled U.S. Army Medical Research and Development Command
NaSingle-groupOpen-labelPrevention

Summary

This study is to collect safety and immunogenicity data for an Rift Valley Fever (RVF) vaccine

Timeline

Start
2018-10-04
Primary completion
2023-12
Completion
2024-12

Drugs

EvaluationDrugModalityDoseRoute
Subject TSI-GSD 200 Vaccine 1 ml Subcutaneous

Indications

Rift valley fever